Judith Balmañà
Vall d'Hebron Hospital Universitari · 623 works · 19,384 citations · h-index 66
Top works
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- A decade of clinical development of PARP inhibitors in perspective
- Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
- Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families
- The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History
- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
- Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing
- A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors
- Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines
- Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline